Logo of Phnom Penh Post newspaper Phnom Penh Post - Sanofi expands to all Cambodia's provinces

Sanofi expands to all Cambodia's provinces

Sanofi expands to all Cambodia's provinces

130222 09
Benoit Martineau, Head of Cambodia and Laos Operations at the Sanofi Group, speaks to the Post this week in Phnom Penh. Photograph: Hong Menea/Phnom Penh Post

During recent weeks, the French-owned Sanofi Group, which has been active in Cambodia for 20 years, took a big step forward. Though the pharmaceutical company’s profits in the Kingdom are relatively small, Sanofi is now planning to expand to all 24 provinces, having stepped up its presence in Southeast Asia with a Cambodian subsidiary in March 2011.

The Post’s Sarah Thust spoke with Benoit Martineau, head of Sanofi’s Cambodia and Laos operations.

Why has Sanofi decided to increase its activities in Cambodia?  

Basically, we think it is important for us to have a dedicated local presence here and to develop our products, but mainly to ensure access for the patient. We drive a strategy based on access. That’s why we have been expanding to all provinces since January. The sales are very small, we are probably losing money doing this, but we think it is important.

Sanofi’s main business in Cambodia is to import, promote and distribute more than 70 pharmaceutical products and vaccines addressing key therapeutic areas (cardiovascular disease, diabetes, internal medicine, pediatrics, infectious diseases and public health). We will also actively participate in various medical education programmes in Cambodia, as well as undertake humanitarian action.

Sanofi is very dedicated to Indochina, as the growth is very high compared to the rest of the Southeast Asian market. In 2010, emerging markets contributed 29.9 per cent to group sales.

Why is growth in the Indochina market so high?    

First of all, it was a rather underdeveloped market, if you consider the size of the population (90 million in Vietnam, 15 million in Cambodia, seven million in Laos).

Also, we want people to be able to access our medicine. Before, in Cambodia, people in the provinces were not able for a long time to access high-quality medicine. Vietnam is a little bit different, because a big part of the market is in the public sector. The Vietnamese government also recently decided to develop access in district hospitals. On the other side, Thailand is a much bigger market that is still growing, but at a slower pace. Singapore and Malaysia also have a bigger market.

In Vietnam, we are a leader, as we have been there for 40 years. We now have the luxury to focus on Cambodia, while others are still trying to settle down and establish their presence in Vietnam. We will continue to focus heavily on Vietnam, where we have more than 1,000 employees, two factories and a third one starting soon.  

Bayer also plans to expand to Cambodia’s provinces. Are you worried about competitors?     

Currently, we’re ahead of all the competitors, but they will start. Bayer started, I guess GSK will make a move soon to set up an affiliate. However, due to the shape of the market and the lack of regulations competitors are working together rather than competing. That is why we set up the pharma working group at the Eurocham.

The position of Cambodia is rather difficult. From a pure business perspective, it’s a small market. The neighbouring countries have a much higher population. But it’s wrong to only address this on a business perspective. What we want to address is the patient’s perspective, which is rather a long-term strategy.

What still needs to be done?    

In Cambodia, the market is more open and that’s a problem. While countries in Europe or the United States have only few distributors for medicine, Cambodia has about 200. The barrier to enter the market is rather limited. We’re trying to support the authorities to shape the market, to create more rules.

On the manufacturing perspective, the problem Cambodia will face are the neighbours that put a lot of focus on pharma. Currently, Cambodia is not seen as the first priority for multinationals to invest in factories, especially as manufacturing requires a lot of skills and experience, which currently is limited in Cambodia, but available in Thailand and Vietnam. That’s why we have factories in Vietnam, Thailand, Indonesia and Singapore.

It is the job of the government to make the market more attractive.
 
Public health experts in Cambodia criticised Sanofi for trials for a dengue vaccine conducted in neighbouring Thailand, saying the outcome would be too expensive for those who need it. What do you say to that?

We recently signed an agreement with the Thai government to develop local medicine. In Cambodia we only do small studies. The lack of expertise in Cambodia’s
labour force doesn’t allow us to go further.

However, we also supply NGOs. Our program Access Medicine allows us to offer therapeutic solutions at an accessible price. For example, we try to find a way to provide cheap and high-quality products against epilepsy in Cambodia.

To contact the reporter on this story: Sarah Thust at [email protected]
 

MOST VIEWED

  • Proof giants walked among us humans?

    For years a debate has waged about whether certain bas relief carvings at the 12th-century To Prohm Temple, one of the most popular attractions at the Angkor Wat Temple Complex in Siem Reap province, depicted dinosaurs or some rather less exotic and more contemporary animal,

  • Japan bank buys major stake in ANZ Royal Bank

    Japan's largest bank acquired more than half of ANZ’s shares in Cambodia on Thursday, according to a statement from Kith Meng’s Royal Group. Japan's JTrust Bank, announced that they had acquired a 55% of stake in ANZ Royal Bank. According to a Royal Group

  • Long way to go before Cambodia gets a ‘smart city’

    Phnom Penh, Siem Reap and Battambang will struggle to attain smart city status without adopting far reaching master plans, according to officials tasked with implementing the program. The brainchild of the Association of Southeast Asian Nations (Asean), the smart city program seeks to link up

  • New US bill ‘is a violation of Cambodian independence’

    After a US congressmen introduced bipartisan legislation that will enact sanctions on Cambodian officials responsible for “undermining democracy” in the Kingdom, government officials and the ruling Cambodian People’s Party on Sunday said they regarded the potential action as the “violation of independence and sovereignty